Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Peripheral Blood Stem Cells versus Bone Marrow for T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma.

Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, Granata A, Maisano V, Pagliardini T, De Philippis C, Kogan M, Faucher C, Harbi S, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1810-1817. doi: 10.1016/j.bbmt.2019.05.017. Epub 2019 May 22.

PMID:
31128326
2.

Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2019 May;49(9):1181-1187. doi: 10.1111/apt.15223. Epub 2019 Apr 1.

PMID:
30932219
3.

MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation.

Crisafulli L, Muggeo S, Uva P, Wang Y, Iwasaki M, Locatelli S, Anselmo A, Colombo FS, Carlo-Stella C, Cleary ML, Villa A, Gentner B, Ficara F.

Haematologica. 2019 Sep;104(9):1744-1755. doi: 10.3324/haematol.2018.198499. Epub 2019 Feb 21.

4.

The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.

Mariotti J, Granata A, Bramanti S, Devillier R, Furst S, Sarina B, Harbi S, Legrand F, Faucher C, Weiller PJ, Chabannon C, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2019 Jul;54(7):1164-1167. doi: 10.1038/s41409-019-0453-0. Epub 2019 Jan 24.

PMID:
30679826
5.

Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.

Mariotti J, De Philippis C, Bramanti S, Sarina B, Tordato F, Pocaterra D, Casari E, Carlo-Stella C, Santoro A, Castagna L.

Eur J Haematol. 2019 Apr;102(4):357-367. doi: 10.1111/ejh.13214. Epub 2019 Feb 13.

PMID:
30672611
6.

Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Righi M, Locatelli SL, Carlo-Stella C, Presta M, Giacomini A.

Sci Rep. 2018 Nov 30;8(1):17520. doi: 10.1038/s41598-018-35788-4.

7.

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.

Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, Vakkalanka S, Castagna L, Santoro A, Allavena P, Sica A, Carlo-Stella C.

Clin Cancer Res. 2019 Feb 1;25(3):1098-1112. doi: 10.1158/1078-0432.CCR-18-1133. Epub 2018 Oct 23.

PMID:
30352904
8.

Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?

Carbone A, Gloghini A, Carlo-Stella C.

Blood. 2018 Jul 5;132(1):17-22. doi: 10.1182/blood-2018-02-833806. Epub 2018 May 1. Review.

PMID:
29716887
9.

A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.

Sarina B, Mariotti J, Bramanti S, Morabito L, Crocchiolo R, Rimondo A, Tordato F, Pocaterra D, Casari E, De Philippis C, Carlo-Stella C, Santoro A, Castagna L.

Transpl Infect Dis. 2018 Aug;20(4):e12906. doi: 10.1111/tid.12906. Epub 2018 May 16.

PMID:
29668124
10.

Genomic Integration of HHV-6 Mimicking Viral Reactivation after Autologous Stem Cell Transplantation.

Mineri R, Mariotti J, Sarina B, Morabito L, Crocchiolo R, Bramanti S, Sarno T, Tordato F, Carlo-Stella C, Santoro A, Castagna L.

Mediterr J Hematol Infect Dis. 2018 Feb 15;10(1):e2018013. doi: 10.4084/MJHID.2018.013. eCollection 2018.

11.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.

PMID:
29449275
12.

Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.

Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, Granata A, Faucher C, Harbi S, Morabito L, Weiller PJ, Chabannon C, Mokart J, Mineri R, Carlo-Stella C, Santoro A, Blaise D, Castagna L.

Bone Marrow Transplant. 2018 Mar;53(3):366-370. doi: 10.1038/s41409-017-0032-1. Epub 2017 Dec 21. No abstract available.

PMID:
29269800
13.

T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.

Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, Faucher C, Harbi S, Morabito L, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L.

Biol Blood Marrow Transplant. 2018 Mar;24(3):627-632. doi: 10.1016/j.bbmt.2017.11.030. Epub 2017 Nov 29.

14.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.

15.

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL.

Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3.

16.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):797. doi: 10.1038/bmt.2017.26. No abstract available.

PMID:
28465624
17.

Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.

Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):683-688. doi: 10.1038/bmt.2016.348. Epub 2017 Jan 16. Erratum in: Bone Marrow Transplant. 2017 May;52(5):797.

PMID:
28092347
18.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, François S, Stamatoullas-Bastard A, Rohrlich PS, Labussière Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P.

Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.

19.

Estrogen receptor β ligation inhibits Hodgkin lymphoma growth by inducing autophagy.

Pierdominici M, Maselli A, Locatelli SL, Ciarlo L, Careddu G, Patrizio M, Ascione B, Tinari A, Carlo-Stella C, Malorni W, Matarrese P, Ortona E.

Oncotarget. 2017 Jan 31;8(5):8522-8535. doi: 10.18632/oncotarget.14338.

20.

Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.

Locatelli SL, Careddu G, Stirparo GG, Castagna L, Santoro A, Carlo-Stella C.

Sci Rep. 2016 Oct 21;6:35745. doi: 10.1038/srep35745.

21.

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D.

Bone Marrow Transplant. 2016 Dec;51(12):1644-1646. doi: 10.1038/bmt.2016.257. Epub 2016 Oct 17. No abstract available.

PMID:
27748737
22.

The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, Carlo-Stella C.

Leukemia. 2016 Dec;30(12):2402-2405. doi: 10.1038/leu.2016.224. Epub 2016 Aug 8. No abstract available.

PMID:
27499137
23.

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C.

J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466. Epub 2016 Jul 5.

24.

Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.

Bramanti S, Nocco A, Mauro E, Milone G, Morabito L, Sarina B, Crocchiolo R, Timofeeva I, Capizzuto R, Carlo-Stella C, Santoro A, Castagna L.

Transfusion. 2016 May;56(5):1096-1100. doi: 10.1111/trf.13523. Epub 2016 Mar 28.

PMID:
27021516
25.

The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D.

Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21. No abstract available.

PMID:
26999460
26.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Bone Marrow Transplant. 2016 Mar;51(3):470. doi: 10.1038/bmt.2015.327. No abstract available.

PMID:
26931485
27.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Bone Marrow Transplant. 2016 Mar;51(3):462-5. doi: 10.1038/bmt.2015.289. Epub 2015 Nov 23. No abstract available. Erratum in: Bone Marrow Transplant. 2016 Mar;51(3):470. Cheikh, J El [corrected to El-Cheikh, J].

PMID:
26595078
28.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L, Blaise D.

Bone Marrow Transplant. 2016 Feb;51(2):194-8. doi: 10.1038/bmt.2015.270. Epub 2015 Nov 9.

PMID:
26551778
29.

Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.

Carlo-Stella C, Santoro A.

Biomark Med. 2015;9(8):807-17. doi: 10.2217/BMM.15.30. Epub 2015 Jul 30. Review.

PMID:
26223461
30.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Crocchiolo R, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B, Bramanti S, Granata A, Vai A, Harbi S, Morabito L, Mohty B, Giordano L, Devillier R, Coso D, Balzarotti M, Chabannon C, Carlo-Stella C, Santoro A, Bouabdallah R, Blaise D.

Haematologica. 2015 Oct;100(10):e423-7. doi: 10.3324/haematol.2015.129452. Epub 2015 Jul 23. No abstract available.

31.

Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.

Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C.

J Pathol. 2015 Sep;237(1):4-13. doi: 10.1002/path.4558. Epub 2015 Jun 3. Review.

PMID:
25953622
32.

Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.

Castagna L, Carlo-Stella C, Mazza R, Santoro A.

Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015015. doi: 10.4084/MJHID.2015.015. eCollection 2015. Review.

33.

Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, Gandolfi S, Tentorio P, Sarina B, Timofeeva I, Santoro A, Carlo-Stella C, Bruno B, Carniti C, Corradini P, Gostick E, Ladell K, Price DA, Roederer M, Mavilio D, Lugli E.

Blood. 2015 Apr 30;125(18):2855-64. doi: 10.1182/blood-2014-11-608406. Epub 2015 Mar 5.

34.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A.

Oncologist. 2015 Mar;20(3):323-8. doi: 10.1634/theoncologist.2014-0420. Epub 2015 Feb 10.

35.

Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L.

Transpl Infect Dis. 2015 Apr;17(2):242-9. doi: 10.1111/tid.12365.

PMID:
25648539
36.

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A.

Bone Marrow Transplant. 2015 Apr;50(4):499-504. doi: 10.1038/bmt.2014.304. Epub 2015 Jan 26.

PMID:
25621797
37.

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.

Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G, Carlo-Stella C, Santoro A, Rahal D, Totonchy J, Elemento O, Cesarman E, Roshal M.

Blood. 2015 Feb 12;125(7):1061-72. doi: 10.1182/blood-2014-11-610436. Epub 2014 Dec 8.

PMID:
25488972
38.

B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY.

Roberto A, Castagna L, Gandolfi S, Zanon V, Bramanti S, Sarina B, Crocchiolo R, Todisco E, Carlo-Stella C, Tentorio P, Timofeeva I, Santoro A, Della Bella S, Roederer M, Mavilio D, Lugli E.

Bone Marrow Transplant. 2015 Feb;50(2):317-9. doi: 10.1038/bmt.2014.266. Epub 2014 Nov 24. No abstract available.

PMID:
25419693
39.

High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.

Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM.

Ann Oncol. 2015 Jan;26(1):167-72. doi: 10.1093/annonc/mdu485. Epub 2014 Oct 24.

PMID:
25344361
40.

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Cell Death Dis. 2014 Oct 2;5:e1434. doi: 10.1038/cddis.2014.410.

41.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

42.

Role of alpha-synuclein in autophagy modulation of primary human T lymphocytes.

Colasanti T, Vomero M, Alessandri C, Barbati C, Maselli A, Camperio C, Conti F, Tinari A, Carlo-Stella C, Tuosto L, Benincasa D, Valesini G, Malorni W, Pierdominici M, Ortona E.

Cell Death Dis. 2014 May 29;5:e1265. doi: 10.1038/cddis.2014.211.

43.

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

44.

The role of inflammation in lymphoma.

Carbone A, Tripodo C, Carlo-Stella C, Santoro A, Gloghini A.

Adv Exp Med Biol. 2014;816:315-33. doi: 10.1007/978-3-0348-0837-8_12. Review.

PMID:
24818728
45.

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.

Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, Santoro A.

Br J Haematol. 2014 Jul;166(1):140-2. doi: 10.1111/bjh.12821. Epub 2014 Mar 7. No abstract available.

PMID:
24606548
46.

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A, Carlo-Stella C.

Leukemia. 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81. Epub 2014 Feb 24.

PMID:
24561519
47.

Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.

Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B, Granata A, Mauro E, Faucher C, Mohty B, Harbi S, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Biol Blood Marrow Transplant. 2014 May;20(5):724-9. doi: 10.1016/j.bbmt.2014.02.001. Epub 2014 Feb 13.

48.

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM.

Bone Marrow Transplant. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20.

PMID:
24442244
49.

Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy.

Necchi A, Miceli R, Pedrazzoli P, Giannatempo P, Secondino S, Di Nicola M, Farè E, Raggi D, Magni M, Matteucci P, Longoni P, Milanesi M, Paternò E, Ravagnani F, Arienti F, Nicolai N, Salvioni R, Carlo-Stella C, Gianni AM.

Clin Genitourin Cancer. 2014 Jun;12(3):196-202.e1. doi: 10.1016/j.clgc.2013.11.021. Epub 2013 Nov 13.

PMID:
24361054
50.

Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.

Farina L, Guidetti A, Spina F, Roncari L, Longoni P, Ravagnani F, Carlo-Stella C, Corradini P.

Bone Marrow Transplant. 2014 Mar;49(3):453-5. doi: 10.1038/bmt.2013.193. Epub 2013 Dec 9. No abstract available.

PMID:
24317127

Supplemental Content

Loading ...
Support Center